Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

PRO-LAD

PRO-LAD molecule structurePRO-LAD molecule structure
6-Propyl-6-nor-lysergic acid diethylamide
N-PropylnorLSD, 6-propyl-6-nor-LSDOpen in Piru
Psychoactive Class
PsychedelicHallucinogen
Chemical Class
Lysergamide

PRO-LAD is structurally analogous to LSD.1 It differs from LSD by having a propyl group in place of a methyl group at the 6-position of its chemical structure.1 It is taken orally.2

Dosage & Duration

Log in Piru

Dosage

Doses are population estimates that vary widely between individuals.

Threshold20 µg
Light50-100 µg
Moderate100-150 µg
Strong150-200 µg
Heavy350+ µg

Duration

Onset30-45 minutes
Total6-8 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Effects vary widely by individual, dose, and context.

Physical

Bodily control enhancementNauseaPupil dilationSpontaneous tactile sensationsStimulationTactile enhancement

Cognitive

Analysis enhancementConceptual thinkingCreativity enhancementDelusionsEmotion enhancementImmersion enhancementMemory suppressionEgo deathMindfulnessNovelty enhancementPersonal bias suppressionSpirituality enhancementThought accelerationThought disorganizationThought loopsTime distortionUnity and interconnectednessWakefulness

Visual

Distortions

Enhancements

Hallucinatory States

Transformations

Auditory

EnhancementsDistortionsHallucinations
Forked from Subjective Effect Documentation work byJosie Kins August 2016.

See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)

Pharmacology

Pharmacodynamics

PRO-LAD acts as a partial agonist at the serotonin 5-HT2A receptor. It also shows affinity for 5-HT1A and 5-HT2C receptors.3 In rat drug discrimination tests, it substituted for LSD.4

Pharmacokinetics

PRO-LAD's propyl substituent has been proposed to slow its absorption, but this remains uncertain.

Metabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

Lithium

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

Tramadol

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

AmphetaminesCannabisCocaineDiphenhydramineMephedronePregabalin
Powered by TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
Tolerance to PRO-LAD develops almost immediately after ingestion.
Baseline Reset
Tolerance returns to baseline after approximately 14 days without further PRO-LAD consumption.
Half Tolerance
Tolerance falls to approximately half its initial level within 5–7 days, provided no further PRO-LAD is consumed.
Cross Tolerance

All psychedelics

Harm Potential

Addiction & Dependence

Psychological

Extremely Low

Formal studies are lacking, but PRO-LAD is described as having low habit-forming potential, and repeated use may reduce desire for further use.

Toxicity

Lethal Dosage

The exact toxic dose is described as unknown, and long-term health effects have not been studied in a scientific context.

central nervous system

Combining PRO-LAD with MDMA is described as unpredictable and likely neurotoxic.

Psychosis Risk

Low

Psychosis is described mainly as a risk with discouraged combinations such as lithium, cannabis, or stimulants.

Seizure Risk

Low

Seizure is described as very rare, likely limited to predisposed people or risky combinations; no documented cases with PRO-LAD were noted.

History & Culture

PRO-LAD was first described in the scientific literature by Tetsukichi Niwaguchi and colleagues in 1976. Andrew J. Hoffman and David E. Nichols subsequently studied and described it in 1985.2 In 1986, Nichols published the first account of its hallucinogenic effects in…

Legality

By Country

Illegal5
Austria flagAustriaIllegal (analog/blanket ban)
Germany flagGermanyIllegal (analog/blanket ban)
Latvia flagLatviaIllegal (analog/blanket ban)
Switzerland flagSwitzerlandIllegal
United Kingdom flagUnited KingdomIllegal

References

Source Pages

  1. Erowid TiHKAL Entry #51: PRO-LAD
  2. Isomer Design (TiHKAL/PiHKAL)
  3. PsychonautWiki
  4. Shulgin A, Shulgin A (1997). TiHKAL: Tryptamines I Have Known And Loved
  5. TripSit Factsheets
  6. TripSit: Drug Combination Chart
  7. Wikipedia

Citations

  1. Addendum to ACMD’s report on tryptamines. Advisory Council on the Misuse of Drugs (2014). https://assets.publishing.service.gov.uk/media/5a7e012fe5274a2e8ab4537b/AddendumTryptaminesOct14.pdf12
  2. Analytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P‐AL‐LAD. Drug Testing and Analysis (2022). https://doi.org/10.1002/dta.328112
  3. Mapping the Binding Site of the 5-HT2A Receptor Using Mutagenesis and Ligand Libraries: Insights into the Molecular Actions of Psychedelics. Purdue University (2012). https://isomerdesign.com/bitnest/external/Theses/McCorvey20121
  4. Synthesis and LSD-like discriminative stimulus properties in a series of /N(6)-alkyl norlysergic acid /N,/N-diethylamide derivatives. Journal of Medicinal Chemistry (1985). https://doi.org/10.1021/jm00147a0221
  5. Par Krimināllikuma spēkā stāšanās un piemērošanas kārtību — 2. pielikums, II nodaļas 11. punkta 21. apakšpunkts. likumi.lv (n.d.). https://likumi.lv/ta/id/50539-par-kriminallikuma-speka-stasanas-un-piemerosanas-kartibu1
  6. Narkotisko un psihotropo vielu un zāļu, kā arī prekursoru likumīgās aprites likums — 3. un 5. pants. likumi.lv (n.d.). https://likumi.lv/ta/id/40283-par-narkotisko-un-psihotropo-vielu-un-zalu-likumigas-aprites-kartibu1
  7. Ministru kabineta 2015. gada 26. maija noteikumi Nr. 256. likumi.lv (n.d.). https://likumi.lv/ta/id/274341-grozijumi-ministru-kabineta-2005-gada-8-novembra-noteikumos-nr-847-noteikumi-par-latvija-kontrolejamajam-narkotiskajam-vielam-psihotropajam-vielam-un-prekursoriem1
  8. Ministru kabineta 2017. gada 7. marta noteikumi Nr. 126. likumi.lv (n.d.). https://likumi.lv/ta/id/289280-grozijumi-ministru-kabineta-2005-gada-8-novembra-noteikumos-nr-847-noteikumi-par-latvija-kontrolejamajam-narkotiskajam-vielam-psihotropajam-vielam-un-prekursoriem1
  9. PubChem PUG REST — Pro-lad, CID 44457803. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/44457803/property/IUPACName,Title,MolecularFormula,CanonicalSMILES,IsomericSMILES,InChIKey/JSON1
  10. PubChem PUG REST — PRO-LAD (CID 44457803) synonyms. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/44457803/synonyms/JSON1

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the PRO-LAD article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.